ANKRD44 anticorps (Middle Region)

N° du produit ABIN950427

Détail du produit anti-ANKRD44 anticorps

Antigène: ANKRD44 (Ankyrin Repeat Domain 44 (ANKRD44))

Épitope: AA 484-514, Middle Region

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp ANKRD44 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Specificité: This antibody reacts to ANKRD44.

Réactivité croisée (Details): Species reactivity (tested):Human.

Purification: Affinity chromatography on Protein A

Immunogène: KLH conjugated synthetic peptide between 484-514 amino acids from the Central region of human ANR44

Isotype: Ig Fraction

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.25 mg/mL

Buffer: PBS containing 0.09 % (W/V) sodium azide as preservative

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur ANKRD44

Antigène: ANKRD44 (Ankyrin Repeat Domain 44 (ANKRD44))

Autre désignation: ANKRD44 (ANKRD44 Produits)

Synonymes: anticorps PP6-ARS-B, anticorps 4930444A19Rik, anticorps A130096K20, anticorps E130014H08Rik, anticorps ankyrin repeat domain 44, anticorps ANKRD44, anticorps Ankrd44

Sujet: Putative regulatory subunit of protein phospatase 6 (PP6) that may be involved in the recognition of phosphoprotein substrates.Synonyms: Ankyrin repeat domain-containing protein 44, PP6-ARS-B, Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit B, Serine/threonine-protein phosphatase 6 regulatory subunit ARS-B

ID gène: 91526

NCBI Accession: NP_001182073